ArticleFrontiers in immunology2026
Recurrent antibody repertoire features associated with six selected human IGHV genes: V(D)J usage, heavy-light pairing, and CDRH3 properties.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Several human IGHV genes recur in infection, autoreactivity, B-cell malignancy, and antibody-discovery studies, but their downstream V(D)J usage, observed heavy-light pairing, and CDRH3 properties have rarely been examined together in paired human repertoires. Methods: We assembled 3,003,127 paired heavy- and light-chain records from public Observed Antibody Space (OAS) source files. After quality control, gene-level standardization, and exact-clonotype collapsing, the primary six-gene analysis included 712,143 exact clonotypes assigned to IGHV1-2, IGHV1-69, IGHV3-21, IGHV3-23, IGHV3-30, or IGHV4-34. Results: Marginal V-D effects were generally modest, whereas recurrent V-conditioned D-J modules and IGHV-associated VH-VL enrichment or depletion were repeatedly observed across OAS study groups in productive expressed repertoires. Several VH-VL directions persisted across studies and metadata-defined immune contexts, although two pairs were context-sensitive. External comparison with PairedAbNGS supported 8 of 10 evaluable key VH-VL directions and the broad IGHV-associated CDRH3 profiles. IGHV4-34 showed a study-robust, cross-resource positive shift in CDRH3 side-chain charge score. Discussion: Together, these analyses provide a study-aware reference for V-conditioned D-J usage, VH-VL associations, and CDRH3 properties across six selected IGHV backgrounds, while defining the limits imposed by immune-context heterogeneity and productive-repertoire sampling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.